目的 分析真實世界中益氣維血治療貧血相關(guān)性疾病的臨床特征及有效性，為臨床應(yīng)用提供借鑒和參考。方法 采用頻數(shù)分析對來自7個省市18家綜合醫(yī)院信息系統(tǒng)（ HIS）中使用益氣維血治療貧血患者一般信息、診斷信息及臨床用藥信息進(jìn)行統(tǒng)計分析。采用Apriori算法建立模型，運用SPSS Modeler 18.0對數(shù)據(jù)進(jìn)行關(guān)聯(lián)分析，并通過對比實驗室指標(biāo)對益氣維血療效進(jìn)行分析。結(jié)果 使用益氣維血片/膠囊治療貧血患者共6 629例，女性患者多于男性，比例為3.09∶ 1.00。年齡分布為25～45歲患者比例最大，占50.61%?；颊叻植伎剖乙詪D產(chǎn)科為主。入院診斷病情為輕度貧血的患者最為普遍，占75.50%。使用益氣維血片/膠囊治療貧血患者常合并婦產(chǎn)科相關(guān)疾病，其次是腎相關(guān)疾病、消化道疾病、肝病、惡性腫瘤等。關(guān)聯(lián)規(guī)則分析顯示益氣維血與琥珀酸亞鐵片、復(fù)方硫酸亞鐵葉酸片和右旋糖酐鐵口服液聯(lián)合使用頻率最高，規(guī)則支持度分別為28.70%、18.12%、17.97%。益氣維血聯(lián)合2種藥物使用頻率最高的是右旋糖酐鐵口服液＋復(fù)方硫酸亞鐵葉酸片，規(guī)則支持度為7.54%。有效性分析表明，與單獨使用鐵劑治療貧血的患者相比，使用益氣維血的患者血紅蛋白上升變化更明顯（P＜0.05）。結(jié)論 益氣維血用藥以女性患者為主，臨床合并癥頻數(shù)最多婦產(chǎn)科相關(guān)疾病，聯(lián)合用藥使用最多的是琥珀酸亞鐵片。益氣維血相比于鐵劑治療貧血具有更顯著的療效，有助于貧血患者的恢復(fù)。

Objective To understand the clinical characteristics and efficacy of Yiqi Weixue treatment for anemia-related diseases in the real world, providing reference and guidance for clinical application. Methods Frequency analysis was conducted on general information, diagnosis information, and clinical medication information of patients treated with Yiqi Weixue for anemia, extracted from the Hospital Information Systems (HIS) of 18 general hospitals across seven provinces. The Apriori algorithm was used to establish a model, and SPSS Modeler 18.0 was employed for association analysis of the data. The efficacy of Yiqi Weixue was analyzed by comparing laboratory indicators. Results A total of 6 629 patients were treated with Yiqi Weixue for anemia, with more female patients than male patients at a ratio of 3.09∶ 1.00. The largest proportion of patients (50.61%) were aged from 25 to 45. The main departments where patients were distributed were obstetrics and gynecology. The most common admission diagnosis was mild anemia, accounting for 75.50%. Patients treated with Yiqi Weixue for anemia often had comorbidities related to obstetrics and gynecology, followed by renal diseases, gastrointestinal diseases, liver diseases, and malignancies. Association rule analysis showed that Yiqi Weixue was most frequently used in combination with ferrous succinate tablets, compound ferrous sulfate folic acid tablets, and iron sucrose injection, with support degrees of 28.70%, 18.12%, and 17.97%, respectively. The most frequent combination of two drugs was dextran iron oral solution and compound ferrous sulfate and folic acid tablets, with a support rate of 7.54%. Efficacy analysis indicated that patients using Yiqi Weixue showed more significant increases in hemoglobin levels compared to those treated with iron supplements alone (P < 0.05). Conclusion The clinical use of Yiqi Weixue primarily involves female patients, with the highest frequency of comorbid obstetrics and gynecology. Compared to iron supplements, Yiqi Weixue therapy for anemia shows more significant efficacy, aiding in the recovery of anemic patients.

R973